Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging.
Previously, transscleral and transcorneal iontophoretic delivery was studied and compared to passive delivery and intravitreal injection using nuclear magnetic resonance imaging (MRI). The objective of the present study was to employ MRI to further investigate the factors affecting transscleral iontophoretic delivery. In the present study, anodal and cathodal constant current transscleral iontophoresis were conducted with excised sclera in side-by-side diffusion cells in vitro and with rabbits in vivo. The total current and duration of application were 2 and 4mA (current density 10 and 20mA/cm(2)) and 20-60min, respectively. The delivery and distribution of the model permeants manganese ion (Mn(2+)) and manganese ethylenediaminetetraacetic acid complex (MnEDTA(2-)) into the eye during iontophoresis were determined with MRI and compared with the results obtained in previous studies of subconjunctival injection and passive delivery. Both anodal and cathodal iontophoresis provided significant enhancement in ocular delivery compared to passive transport in the in vitro and in vivo experiments. Transscleral iontophoretic delivery was related to the position and duration of the iontophoresis application in vivo. Permeants were observed to be delivered primarily into the anterior segment of the eye when the pars plana was the application site. Extending the duration of iontophoresis at this site allowed the permeants to be delivered into the vitreous more deeply and to a greater extent than when the application site was at the back of the eye near the fornix. The present results show that electrode placement was an important factor in transscleral iontophoresis, and the ciliary body (pars plana) was determined to be the pathway of least resistance for iontophoretic transport. These new findings continue to support the utility of MRI as a noninvasive technique in ocular drug delivery research and testing.
Molokhia
Sarah A
SA
Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Jeong
Eun-Kee
EK
Department of Radiology and Utah Center for Advanced Imaging Research, University of Utah, Salt Lake City, UT 84108, USA.
Higuchi
William I
WI
Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Li
S Kevin
SK
Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA. Electronic address: kevin.li@uc.edu.
D000287:Administration, Topical; D000818:Animals; D000869:Anterior Eye Segment / Q000378:metabolism; D002712:Chlorides / Q000008:administration & dosage* / Q000378:metabolism; D002924:Ciliary Body / Q000378:metabolism*; D003228:Conjunctiva / Q000378:metabolism; D004058:Diffusion; D015194:Diffusion Chambers, Culture; D016503:Drug Delivery Systems; D007267:Injections; D007478:Iontophoresis / Q000379:methods; D008279:Magnetic Resonance Imaging; D017895:Manganese Compounds / Q000008:administration & dosage* / Q000378:metabolism; D010539:Permeability; D011817:Rabbits; D012590:Sclera / Q000378:metabolism*; D013997:Time Factors; D014822:Vitreous Body / Q000378:metabolism
D002712:Chlorides; D017895:Manganese Compounds; C025340:manganese chloride